Resources Blog Antibody-Drug Conjugates: A New Frontier in Cancer Treatment

Antibody-Drug Conjugates: A New Frontier in Cancer Treatment

Biointron 2024-01-20 Read time: 1 min
ADCs.jpg
Image credit: DOI: 10.1007/s00277-021-04599-5

Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody (mAbs) covalently bonded to a biologically active cytotoxic drug via a chemical linker. The mAb can then bind to a specific target protein or receptor, allowing the delivery of the drug into the target cell. 

This combination allows for a highly specific targeting and potent killing effect to achieve accurate and efficient elimination of target cells, without harming healthy cells. This is particularly desirable in treating cancer, as chemotherapy has poor specificity towards tumor tissues and has toxicities to healthy tissues.1

Although most developed ADCs are designed to treat cancer, ongoing research are attempting to use ADCs to treat different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. Furthermore, development of bispecific ADCs, as well as combinations of ADCs with immunotherapy, are anticipated to produce more safe and efficacious therapies.2

At Biointron, we are dedicated to accelerating antibody discovery for the development of antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


References:

  1. Pettinato, M. C. (2021). Introduction to Antibody-Drug Conjugates. Antibodies, 10(4). https://doi.org/10.3390/antib10040042 

  2. Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(1), 1-25. https://doi.org/10.1038/s41392-022-00947-7

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024
Blog

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024
Blog

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024
Blog

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024
Blog

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.